Roche forges deal with San Diego biotech, betting on new antibiotic class
The coronavirus outbreak may be monopolizing the airwaves, but that doesn’t mean the tsunami of antibiotic resistance isn’t still incoming.
But there is some encouraging progress, despite the majority of big pharma abandoning the beleaguered field of antibiotics. On Wednesday, Roche tied up with San Diego-based Forge Therapeutics in a research pact, which gives the Swiss drugmaker the option to license an experimental antibiotic being developed for use in serious lung infections.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.